Amid Covid-19 hunt, Pfizer adds Lyme disease vaccine in $308M deal with Valneva
In the midst of their $500 million program to build a Covid-19 vaccine with BioNTech, Pfizer has announced a sizable deal to commercialize a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
